Further in vivo experiments using patient-derived xenograft models showed that TAK-960 treatment was effective in 6 out of 18 CRC xenograft models, which was not associated with the KRAS, BRAF, NRAS, PIK3CA, or TP53 mutation status[59]. This evidence concerns the gene KRAS and colorectal carcinoma.